there is an ever increasing competitiveness forcing firms to accelerate identification of promising, novel compounds / partners and assess promising candidates from the external R&D market place. The presentation addresses how integrated intelligence initiatives could be leveraged to qualify early stage assets and time tested frameworks that could help point and value a potential asset for investment.
• Thus, there is limited 3rd party, objective data on rare diseases
• This is more pronounced in emerging markets like Asia, where information for big pharma is sketchy at best
• The above scenario results in utilization of different strategies to determine the competitive landscape; techniques less frequently if ever used in big pharma
• FDA issues, ongoing mergers, biosimilars opportunity, recent news
• US FDA compliance issues with companies in India
• The rise of China and Japan as a player in US generic Drug industry
strategy. It is irrelevant to the business and operates in an organisational vacuum. This workshop will provide you an introduction to Competitive Intelligence, and how to run a demand driven and decision supportive competitive intelligence process that focus on understanding the competitive environment, the strategic intent and future initiatives of your key competitors and other market stakeholders. We will combine traditional training with some hands on exercises to help you implement our training in your day to day work back at the office, to ensure you are tightly connected to business imperatives and have a decisive impact on your business decision making and strategy.
• How can MA and payer discussions complement CI in this process?
• How can Payer research input in the forecasting?
• Valuation of an asset using CI